Lifeboat Foundation

In this video, Drs Irina and Mike Conboy talk about their theory of why we age and introduce Neutral Blood Exchange, which came from their original parabiosis experiments documented in a 2005 paper.

Our guests today are Drs. Irina and Michael Conboy of the Department of Bioengineering at the University of California Berkeley. their discovery of the rejuvenating effects of young blood through parabiosis in a seminal paper published in Nature in 2005 paved the way for a thriving field of rejuvenation biology. The Conboy lab currently focuses on broad rejuvenation of tissue maintenance and repair, stem cell niche engineering, elucidating the mechanisms underlying muscle stem cell aging, directed organogenesis, and making CRISPR a therapeutic reality.

Continue reading “Our Theory Of Aging & Blood Dilution w/ Saline & Albumin | Drs. Irina & Mike Conboy Interview Ep 1” »

Replacing Aging — Dr. Jean M. Hebert, Ph.D. Albert Einstein College of Medicine.

Dr. Jean M. Hebert, Ph.D. (https://einsteinmed.org/faculty/9069/jean-hebert/) is Professor in the Department of Genetics and in the Dominick P. Purpura Department of Neuroscience, at Albert Einstein College of Medicine.

Continue reading “Dr. Jean M. Hebert, Ph.D. — Replacing Aging — Albert Einstein College of Medicine” »

“Prime Editing is a wonderful example of the revolution in genetic medicine that we are living through,” said Robert Nelsen, co-founder and Managing Director of ARCH Venture Partners, one of several companies to fund Prime Medicine. “Gene editing technologies like this, when mature, could totally change our conception of what’s possible in treating disease.”

“This is an opportunity to take a giant step toward cures for a much wider range of diseases than previously possible,” said Stephen Knight, President and Managing Partner of F-Prime Capital, another backer of the new company.

The funds raised will be used to continue building the company, expand the capabilities of its technology platform and rapidly advance towards clinical indications. By the end of 2021, Prime Medicine expects to employ more than 100 people full-time.

Investing in the convergence of bioelectrics & biologics for regeneration & healing — howard J. leonhardt, founder, leonhardt ventures.

Howard Leonhardt is the Founder of Leonhardt Ventures, the world’s first Innovation Accelerator focused on the convergence of bioelectrics & biologics for organ regeneration and tissue healing.

Continue reading “Howard Leonhardt — Founder, Leonhardt Ventures — Bioelectrics & Biologics For Regeneration & Healing” »

University of California San Diego scientists have now developed several genetic editing tools that help pave the way to an eventual gene drive designed to stop Culex mosquitoes from spreading disease. Gene drives are designed to spread modified genes, in this case those that disable the ability to transmit pathogens, throughout the targeted wild population.

Genetics toolkit targets less researched Culex mosquitoes, which transmit West Nile virus and avian malaria.

Continue reading “Researchers Create New CRISPR Genetic Tools to Help Contain Mosquito Disease Transmission” »

Here is a snapshot of our talks on synthetic biology. These videos will provide you with a basic understanding and appreciation for this field. These lectures start with an introduction to synthetic biology and go through the major discoveries and ethical controversies that arise from this field. You can check out the full Synthetic Biology Playlist here!

Breast cancer is the leading cause of cancer death in women around the world, responsible for 1700 deaths every day. Although the vast majority of breast cancers are treatable, the most aggressive subtype—triple negative breast cancer (TNBC) – has a high recurrence rate, a high potential for metastasis and shows resistance to conventional treatments, leading to very poor prognosis and survival outcomes. A team of researchers at the Research Institute of the McGill University Health Center (RI-MUHC) conducted a preclinical study and discovered a novel targeted combination therapy that efficiently reduced tumor growth in metastatic breast cancer. Published in Nature Communications, their findings could lead to the development of a novel first line targeted therapy for the treatment of TNBC, with the prospect of rapidly transitioning to clinical trials in humans.

“There is no targeted therapy for TNBC. Chemotherapy treatment can even enrich these tumors in cancer stem cells and be detrimental to the patient, as we have shown in a previous study,” says Dr. Jean-Jacques Lebrun, senior scientist in the Cancer Research Program at the RI-MUHC and principal investigator of the study. “Filling that huge medical gap was our motivation in conducting this study.”

While most breast cancers have one of three main receptors that are like entrance gates for treatments—estrogen, progesterone and a protein called human epidermal growth factor (HER2) – TNBC has none, thus the name triple negative breast cancer. Using state-of-the-art technologies such as gene editing and genome-wide molecular approaches, the team identified two pathways which could be targeted in a therapeutic strategy.

“Once the virus is recognised, the CRISPR enzyme is activated and chops up the virus,” she said.

Paris (AFP)

Scientists have used CRISPR gene-editing technology to successfully block the transmission of the SARS-CoV-2 virus in infected human cells, according to research released Tuesday that could pave the way for Covid-19 treatments.

Continue reading “Gene editing ‘blocks virus transmission’ in human cells” »

Circa 2019

MIT’S new mini cheetah robot is the first four-legged robot to do a backflip. At only 20 pounds the limber quadruped can bend and swing its legs wide, enabling it to walk either right side up or upside down. The robot can also trot over uneven terrain about twice as fast as an average person’s walking speed. (Learn more: http://news.mit.edu/2019/mit-mini-cheetah-first-four-legged-…kflip-0304)

Continue reading “Backflipping MIT Mini Cheetah” »